Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion November 21, 2024
Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization November 19, 2024
First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma November 6, 2024